•   George Lundberg, MD

    Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

    Go to full article published by CAP Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from The Journal of Urology curated by Editor in Chief George Lundberg, MD, who notes: 

    In this study, clinical and basic pathologic findings outperformed molecular typing in predicting outcomes of bladder cancer.

    Go to full paper published in The Journal of Urology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from JAMIA Open curated by Editor in Chief George Lundberg, MD, who notes: 

    This study found a virtual molecular tumor board to be efficient and effective for more than 1,000 patients.

    Go to full paper published in JAMIA Open.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Using Molecular Testing to Guide Treatment for Advanced Colorectal Cancer

    With: Kalpana Kannan, PhD

    A Q&A with Kalpana Kannan, PhD, former Scientist at Cancer Commons Q: Colorectal cancer is common, and although many cases in earlier stages are cured by surgery alone or with adjuvant chemotherapy, it is still a lethal threat for many… Read more »

  •   George Lundberg, MD

    Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

    What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

    Go to full announcement published by the College of American Pathologists.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Determining which cancers may be responsive to immune checkpoint inhibitors is problematic. These investigators discovered that liquid biopsy may provide an answer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt:

    “Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in Nature Medicine  on April 22, 2019, University of California San Diego School of Medicine researchers found that treating patients with personalized, combination therapies improved outcomes in patients with therapy resistant cancers.”

    Go to full article published by UC San Diego Health on April 22, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt:

    “Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

    “Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”

    Go to full article published by Healio on Feb 3, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.